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Respiratory diseases whether communica-
ble or non-communicable, acute or chronic
impact on health of millions of people.
Several research areas, strongly linked
to the pathogenesis of respiratory diseases
have been identified as priorities over-
arching different specialties (1, 2). Some
are related to early origin of lung dis-
ease. Lifestyle choices have obvious conse-
quences as well as environmental factors
related to inhaled particles or pathogens
impacting the integrity of the airways, or
of our microbiote with dysbiose. Lung
defenses are important to preserve our
lungs from aggression. Their changes in life
are important allowing more vulnerability
early in childhood as well as late in life.
Lung diseases are more frequent with aging
and this represents several challenges.
The early origin of lung diseases should
be better analyzed to understand lung
development and prevent diseases impact-
ing adulthood (3). Prenatal factors are
known to influence lung health later in
life with both nutritional deficiencies and
maternal smoking already recognized as
having epigenetic and trans-generational
effects (4). Life expectancy of several con-
genital defects has improved as infants with
cystic fibrosis or neuromuscular disease
benefit from early interventions with new
targeted biological approaches (5). Effec-
tive prevention of several early infections
is important, in order to reduce incidence
of premature death or bronchiolitis with
long term sequelae. The role of microbiote
for the education of the immune system
appear an important challenge, to prevent
allergies to common allergens in the form
of rhinitis or asthma of varying severity,
often persisting into adulthood (6, 7).
Lifestyle can impact lung health
markedly. It is established that nutritional
deficiencies impair lung growth, favor
infections, and can decrease the ability to
control inflammatory processes due, for
instance, to lack of antioxidative factors (8,
9). A decrease of physical activity, often
combined with obesity, impacts on disor-
ders such as asthma. Obesity also leads to
obstructive sleep apnea syndrome (OSAS)
(10). The overall cardiovascular and meta-
bolic consequences of OSAS are now rec-
ognized to be significant and add to the
overall burden of diseases. The physiologic
process involved need to be better under-
stood. Inhaled particles, volatile organic
compounds, active and passive smoking are
major factors in the etiology of chronic
obstructive lung diseases (COPD) (11).
Asthma and COPD are the most prevalent
respiratory diseases placing a major burden
on health care systems. The local and sys-
temic effects of these diseases still deserve
intensive research for prevention and new
targeted therapies.
Among the environmental factors, car-
cinogens found in tobacco smoke are
known to be abundant and contribute to
one of the two most frequent cancers,
which is lung cancer, the first in men
and the second in women. Other carcino-
gens include the radioactive element radon,
which may be released naturally from the
granite below houses (12), or asbestos
extracted from mines and used for building
insulation. All such compounds need to be
identified and environmental exposure to
them minimized.
Lung defenses and infections are at
the crossroads of several specialties. The
integration of our knowledge is impor-
tant, as acute lower respiratory infections
(such as bacterial and viral pneumonia,
influenza, and respiratory syncytial virus
infections) are the third most frequent
cause of death worldwide, accounting for
4.25 million deaths each year. Underly-
ing chronic lung diseases often alter lung
defenses and influence the type infection
found (13, 14). Several chronic lung dis-
eases like interstitial lung disease, cystic
fibrosis, or asthma among other chronic
obstructive disease can be markedly exac-
erbated by the occurrence of infections
(15). Preventions of infections and con-
trol of inflammation induced in such cir-
cumstances are challenges for the future.
New vaccines and antiviral agents are also
needed.
Aging causes a reduction in the gas-
exchange surface of the lungs, which may
lead to a reduced capacity to oxygenate
blood. The airways become more collapsi-
ble, worsening any underlying obstructive
disease (16). Lung defenses are altered and
infections increased in frequency (17). Pre-
vention of undue inflammation related to
environmental factors might decrease the
effects of this natural decline in airway
function. Lung injury related to inhaled
particles or to infections can produce
fibrotic processes related to defects in nat-
ural repair, to alterations in lung matrix
with consequences in diseases like lung
fibrosis and/or to a higher incidence of
autoimmune diseases among older peo-
ple (18). The immune process lead not
only to scaring of distal airways, but also
in some patients to vascular narrowing
and to a higher incidence of pulmonary
arterial hypertension with age (19). With
aging, dysregulation of lung tissue regener-
ation by progenitor cells can occur, leading
to various thoracic malignancies. Malig-
nancy is also related to carcinogens or to
genetic factors and identification of these
may result in more individualized diag-
nostic screening and more personalized
treatment.
New technologies are becoming avail-
able for improved imaging, with more spe-
cific biomarkers and for more precise tar-
geting of metabolic pathways. These should
allow earlier and more specific diagnosis,
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as well as better targeted and personalized
treatments. One can hope that these new
developments will decrease side effects of
current therapies, improving disease out-
comes and promote more healthy aging.
Frontiers in pneumology should reflect all
these new developments.
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